Structural basis of a shared antibody response to SARS-CoV-2

Area of Science:

• Immunology
• Structural Biology
• Virology

Background:

• Understanding neutralizing antibody responses to SARS-CoV-2 is crucial for developing effective vaccines and therapeutics.
• The spike protein's receptor-binding domain (RBD) is a primary target for neutralizing antibodies.

Purpose of the Study:

• To investigate the molecular basis of neutralizing antibody responses against SARS-CoV-2.
• To identify frequently utilized antibody genes targeting the SARS-CoV-2 RBD.
• To elucidate the structural mechanisms of IGHV3-53 antibody binding to the RBD.

Main Methods:

• Analysis of 294 anti-SARS-CoV-2 antibodies.
• Determination of co-crystal structures of neutralizing antibodies with the SARS-CoV-2 RBD at high resolution.
• Structural analysis of antibody-RBD interactions, including germline residue contributions and complementarity-determining region H3 loop characteristics.

Main Results:

• Immunoglobulin G heavy-chain variable region 3-53 (IGHV3-53) is the most prevalent gene used by antibodies targeting the SARS-CoV-2 RBD.
• Co-crystal structures reveal that germline-encoded residues of IGHV3-53 antibodies are key for recognizing the ACE2-binding site.
• This binding mode favors short complementarity-determining region H3 loops and accommodates diverse light chains, with minimal affinity maturation observed.
• IGHV3-53 antibodies demonstrate high potency, suggesting intrinsic effectiveness.

Conclusions:

• The IGHV3-53 gene segment is a dominant feature of potent neutralizing antibody responses to SARS-CoV-2.
• The structural insights into IGHV3-53 antibody binding provide a blueprint for designing antigens that can elicit similar protective immune responses.
• These findings have significant implications for accelerating vaccine design and therapeutic antibody development against SARS-CoV-2.